Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs 上半年销售零收入 歌礼转攻肥胖药物
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand 这家制药公司旗下的三大商业化产品，今年上半年竟然无任何收入进账。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.